FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

0 Lượt xem· 09/21/23
OncLive® On Air
OncLive® On Air
0 Người đăng ký
0
Trong

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Cho xem nhiều hơn

 0 Bình luận sort   Sắp xếp theo


Tiếp theo